Hepatocellular carcinoma (HCC) is primary liver cancer, frequently diagnosed at advanced stages with limited therapeutic options. MicroRNAs (miRNAs) regulate target gene expression and through inhibitory competitive binding of miRNA influence cellular processes including carcinogenesis. Extensive evidence proved that certain miRNA's are specifically expressed in neoplastic tissues of HCC patients and are confirmed as important factors that can participate in the regulation of key signalling pathways in cancer cells. As such, miRNAs have a great potential in the clinical diagnosis and treatment of HCC and can improve the limitations of standard diagnosis and treatment. Long non-coding RNAs (lncRNAs) have a critical role in the development and progression of HCC. HCC-related lncRNAs have been demonstrated to exhibit abnormal expression and contribute to transformation process (such as proliferation, apoptosis, accelerated vascular formation, and gain of invasive potential) through their interaction with DNA, RNA, or proteins. LncRNAs can bind mRNAs to release their target mRNA and enable its translation. These lncRNA-miRNA networks regulate cancer cell expression and so its proliferation, apoptosis, invasion, metastasis, angiogenesis, epithelial-mesenchymal transition (EMT), drug resistance, and autophagy. In this narrative review, we focus on miRNA and lncRNA in HCC tumor tissue and their interaction as current tools, and biomarkers and therapeutic targets unravelled in recent years.

Department of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

Department of Surgery University Hospital in Pilsen and Faculty of Medicine in Pilsen Charles University Alej Svobody 80 323 00 Pilsen Czech Republic

Laboratory of Cancer Treatment and Tissue Regeneration Biomedical Center Faculty of Medicine in Pilsen Charles University Alej Svobody 1665 76 323 00 Pilsen Czech Republic

Laboratory of Translational Cancer Genomics Biomedical Center Faculty of Medicine in Pilsen Charles University Alej Svobody 1665 76 323 00 Pilsen Czech Republic

Zobrazit více v PubMed

Bellan M., et al. Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms. Diabetes Metab. J. 2019;43 doi: 10.4093/dmj.2018.0201. PubMed DOI PMC

Kubota N., et al. Clinicopathological features of hepatocellular carcinoma with fatty change: tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin. Pathol. Int. Apr. 2020;70(4):199–209. doi: 10.1111/pin.12889. PubMed DOI

Morishita A., Oura K., Tadokoro T., Fujita K., Tani J., Masaki T. Micrornas in the pathogenesis of hepatocellular carcinoma: a review. Cancers. 2021;13(3):1–29. doi: 10.3390/cancers13030514. MDPI AG. PubMed DOI PMC

Hemminki K., et al. Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers. Int. J. Cancer. Mar. 2023;152(6):1107–1114. doi: 10.1002/ijc.34308. PubMed DOI

Llovet J.M., et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. Jan. 2021;7(1):6. doi: 10.1038/s41572-020-00240-3. PubMed DOI

Friedman S.L., Neuschwander-Tetri B.A., Rinella M., Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. Jul. 2018;24(7):908–922. doi: 10.1038/s41591-018-0104-9. PubMed DOI PMC

Anstee Q.M., Reeves H.L., Kotsiliti E., Govaere O., Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. Jul. 2019;16(7):411–428. doi: 10.1038/s41575-019-0145-7. PubMed DOI

Hemminki K., et al. Population-attributable fractions of personal comorbidities for liver, gallbladder, and bile duct cancers. Cancers. Jun. 2023;15(12):3092. doi: 10.3390/cancers15123092. PubMed DOI PMC

Tarao K., et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment. Cancer Med. Mar. 2019;8(3):1054–1065. doi: 10.1002/cam4.1998. PubMed DOI PMC

Sung H., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. May 2021;71(3):209–249. doi: 10.3322/caac.21660. PubMed DOI

Ambrozkiewicz F., et al. CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence. BMC Cancer. Aug. 2022;22(1):884. doi: 10.1186/s12885-022-09989-0. PubMed DOI PMC

sheng Ni J., et al. miR-515-5p suppresses HCC migration and invasion via targeting IL6/JAK/STAT3 pathway. Surg. Oncol. Sep. 2020;34:113–120. doi: 10.1016/J.SURONC.2020.03.003. PubMed DOI

Milana F., et al. Surgical strategies for recurrent hepatocellular carcinoma after resection: a review of current evidence. Cancers. Jan. 2023;15(2):508. doi: 10.3390/cancers15020508. PubMed DOI PMC

Sarveazad A., Agah S., Babahajian A., Amini N., Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J. Res. Med. Sci. 2019;24(1):86. doi: 10.4103/jrms.JRMS_1017_18. PubMed DOI PMC

Shi T., Morishita A., Kobara H., Masaki T. The role of long non-coding RNA and microRNA networks in hepatocellular carcinoma and its tumor microenvironment. Int. J. Mol. Sci. Sep. 2021;22(19) doi: 10.3390/ijms221910630. PubMed DOI PMC

Jiang M.-C., Ni J.-J., Cui W.-Y., Wang B.-Y., Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am. J. Cancer Res. 2019;9(7):1354–1366. PubMed PMC

Yu J., Zhang H., Zhang Y., Zhang X. Integrated analysis of the altered lncRNA, microRNA, and mRNA expression in HBV-positive hepatocellular carcinoma. Life. May 2022;12(5):701. doi: 10.3390/life12050701. PubMed DOI PMC

Xu X., et al. The role of MicroRNAs in hepatocellular carcinoma. J. Cancer. 2018;9(19):3557–3569. doi: 10.7150/jca.26350. PubMed DOI PMC

Dragomir M.P., Kopetz S., Ajani J.A., Calin G.A. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut. Apr. 2020;69(4):748–763. doi: 10.1136/gutjnl-2019-318279. PubMed DOI

Rajtmajerová M., Trailin A., Liška V., Hemminki K., Ambrozkiewicz F. Long non-coding RNA and microRNA interplay in colorectal cancer and their effect on the tumor microenvironment. Cancers. Nov. 2022;14(21):5450. doi: 10.3390/cancers14215450. PubMed DOI PMC

Wu W., Liu S., Liang Y., Zhou Z., Liu X. MiR-7 inhibits progression of hepatocarcinoma by targeting KLF-4 and promises a novel diagnostic biomarker. Cancer Cell Int. Dec. 2017;17(1):31. doi: 10.1186/s12935-017-0386-x. PubMed DOI PMC

Hujie G., et al. MicroRNA-10b regulates epithelial–mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma. Cancer Cell Int. Dec. 2018;18(1):10. doi: 10.1186/s12935-018-0508-0. PubMed DOI PMC

Cho H., et al. Serum exosomal MicroRNA, miR-10b-5p, as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. J. Clin. Med. Jan. 2020;9(1):281. doi: 10.3390/jcm9010281. PubMed DOI PMC

Mjelle R., et al. Comprehensive transcriptomic analyses of tissue, serum, and serum exosomes from hepatocellular carcinoma patients. BMC Cancer. Dec. 2019;19(1):1007. doi: 10.1186/s12885-019-6249-1. PubMed DOI PMC

Franck M., Thon C., Schütte K., Malfertheiner P., Link A. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World J. Hepatol. Nov. 2020;12(11):1031–1045. doi: 10.4254/WJH.V12.I11.1031. PubMed DOI PMC

Fu X., et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. Dec. 2018;37(1):52. doi: 10.1186/s13046-018-0677-7. PubMed DOI PMC

Koustas E., et al. An insight into the arising role of MicroRNAs in hepatocellular carcinoma: future diagnostic and therapeutic approaches. Int. J. Mol. Sci. Apr. 2023;24(8):7168. doi: 10.3390/ijms24087168. PubMed DOI PMC

Peng Y., Huang D., Qing X., Tang L., Shao Z. Investigation of MiR-92a as a prognostic indicator in cancer patients: a meta-analysis. J. Cancer. 2019;10(18):4430–4441. doi: 10.7150/jca.30313. PubMed DOI PMC

Fu Y., et al. MiR-221 promotes hepatocellular carcinoma cells migration via targeting PHF2. BioMed Res. Int. May 2019;2019:1–11. doi: 10.1155/2019/4371405. PubMed DOI PMC

Mariam A., et al. Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma: a pilot study. PeerJ. Jan. 2022;10 doi: 10.7717/peerj.12715. PubMed DOI PMC

Zhu Q., et al. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1) BMC Cancer. Dec. 2016;16(1):806. doi: 10.1186/s12885-016-2801-4. PubMed DOI PMC

Koenig A.B., Barajas J.M., Guerrero M.J., Ghoshal K. A comprehensive analysis of argonaute-CLIP data identifies novel, conserved and species-specific targets of miR-21 in human liver and hepatocellular carcinoma. Int. J. Mol. Sci. Mar. 2018;19(3) doi: 10.3390/IJMS19030851. PubMed DOI PMC

Zhou Y., Liu F., Ma C., Cheng Q. Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma. J. Clin. Lab. Anal. Oct. 2022 doi: 10.1002/jcla.24673. PubMed DOI PMC

Yugawa K., et al. Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur. J. Surg. Oncol. Feb. 2021;47(2):384–393. doi: 10.1016/j.ejso.2020.08.002. PubMed DOI

Zhou Y., et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J. Exp. Clin. Cancer Res. Dec. 2018;37(1):324. doi: 10.1186/s13046-018-0965-2. PubMed DOI PMC

Fu X., et al. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. Apr. 2017;108(4):620–631. doi: 10.1111/cas.13177. PubMed DOI PMC

Peng Z. MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma. Front. Biosci. 2018;23(1):4596. doi: 10.2741/4596. PubMed DOI

Ye Y., et al. Induced MiR-1249 expression by aberrant activation of Hedegehog signaling pathway in hepatocellular carcinoma. Exp. Cell Res. Jun. 2017;355(1):9–17. doi: 10.1016/j.yexcr.2017.03.010. PubMed DOI

Song L., et al. miR-4417 targets tripartite motif-containing 35 (TRIM35) and regulates pyruvate kinase muscle 2 (PKM2) phosphorylation to promote proliferation and suppress apoptosis in hepatocellular carcinoma cells. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. Apr. 2017;23:1741–1750. doi: 10.12659/MSM.900296. PubMed DOI PMC

Yang H., et al. Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncol. Lett. Jan. 2018 doi: 10.3892/ol.2018.7879. PubMed DOI PMC

Su S.-G., et al. miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma. Int. J. Biochem. Cell Biol. Oct. 2017;91:53–59. doi: 10.1016/j.biocel.2017.08.016. PubMed DOI

Chen F., Li X.-F., Fu D.-S., Huang J.-G., Yang S.-E. Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma. Cancer Biomarkers. Feb. 2017;18(2):209–214. doi: 10.3233/CBM-161671. PubMed DOI

Chang R.-M., Xiao S., Lei X., Yang H., Fang F., Yang L.-Y. miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma. Clin. Cancer Res. May 2017;23(10):2593–2604. doi: 10.1158/1078-0432.CCR-16-0851. PubMed DOI

Xie R., et al. MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncol. Lett. Jan. 2018 doi: 10.3892/ol.2018.7892. PubMed DOI PMC

Ma Y.-S., et al. High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget. Feb. 2017;8(7):11896–11905. doi: 10.18632/oncotarget.14435. PubMed DOI PMC

Jin Y., Wang J., Han J., Luo D., Sun Z. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway. Exp. Cell Res. Nov. 2017;360(2):210–217. doi: 10.1016/j.yexcr.2017.09.010. PubMed DOI

Liu C., Zhu J., Liu F., Wang Y., Zhu M. MicroRNA-138 targets SP1 to inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells. Oncol. Lett. Jan. 2018;15(1):1279–1286. doi: 10.3892/OL.2017.7357. PubMed DOI PMC

Lin M.-F., et al. FOXK2, regulted by miR-1271-5p, promotes cell growth and indicates unfavorable prognosis in hepatocellular carcinoma. Int. J. Biochem. Cell Biol. Jul. 2017;88:155–161. doi: 10.1016/j.biocel.2017.05.019. PubMed DOI

Guo X., Lv X., Lv X., Ma Y., Chen L., Chen Y. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. Jul. 2017;8(27):44050–44058. doi: 10.18632/oncotarget.17211. PubMed DOI PMC

Zhao X.-F., Li N., Lin D.-D., Sun L.-B. Circulating MicroRNA-122 for the diagnosis of hepatocellular carcinoma: a meta-analysis. BioMed Res. Int. Mar. 2020;2020:1–10. doi: 10.1155/2020/5353695. PubMed DOI PMC

Bharali D., Banerjee B.D., Bharadwaj M., Husain S.A., Kar P. Expression analysis of MicroRNA-21 and MicroRNA-122 in hepatocellular carcinoma. J. Clin. Exp. Hepatol. May 2019;9(3):294–301. doi: 10.1016/j.jceh.2018.07.005. PubMed DOI PMC

Mohamed A.A., et al. MiR-155 and MiR-665 role as potential non-invasive biomarkers for hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. J. Transl. Int. Med. May 2020;8(1):32–40. doi: 10.2478/jtim-2020-0006. PubMed DOI PMC

Han J., et al. Identification of plasma miR-148a as a noninvasive biomarker for hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. Oct. 2019;43(5):585–593. doi: 10.1016/j.clinre.2018.12.008. PubMed DOI

Wu S., Liu S., Cao Y., Chao G., Wang P., Pan H. Downregulation of ZC3H13 by miR-362-3p/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma. Aging. Mar. 2022;14(5):2304–2319. doi: 10.18632/aging.203939. PubMed DOI PMC

Wen D., et al. Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: a comprehensive study using microarray and RNA sequencing data. Oncol. Lett. Sep. 2018 doi: 10.3892/ol.2018.9523. PubMed DOI PMC

Zhang Y., et al. Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development. Cell Death Dis. Dec. 2021;12(12) doi: 10.1038/s41419-021-04436-7. PubMed DOI PMC

Zhou J., et al. LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/β-catenin signaling in hepatocellular carcinoma. Int. J. Med. Sci. 2023;20(1):23–34. doi: 10.7150/ijms.68778. PubMed DOI PMC

Li W., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer. Oct. 2008;123(7):1616–1622. doi: 10.1002/ijc.23693. PubMed DOI

Liang L., et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. Nov. 2010;52(5):1731–1740. doi: 10.1002/hep.23904. PubMed DOI

Yu H., Han R., Su J., Chen H., Li D. Multi-marker diagnosis method for early Hepatocellular Carcinoma based on surface plasmon resonance. Clin. Chim. Acta. Mar. 2020;502:9–14. doi: 10.1016/J.CCA.2019.12.007. PubMed DOI

Wang X., Gao J., Zhou B., Xie J., Zhou G., Chen Y. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Life Sci. Sep. 2019;232 doi: 10.1016/J.LFS.2019.116596. PubMed DOI

Devhare P.B., Steele R., Bisceglie A.M.D., Kaplan D.E., Ray R.B. Differential expression of MicroRNAs in hepatitis C virus-mediated liver disease between african Americans and caucasians: implications for racial Health disparities. Gene Expr. 2017;17(2):89–98. doi: 10.3727/105221616X693594. PubMed DOI PMC

Shi D.-M., Shi X.-L., Xing K.-L., Zhou H.-X., Lu L.-L., Wu W.-Z. miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis. Cell. Signal. Aug. 2020;72 doi: 10.1016/j.cellsig.2020.109650. PubMed DOI

Huo W., Du M., Pan X., Zhu X., Gao Y., Li Z. miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. FEBS Open Bio. Aug. 2017;7(8):1085–1091. doi: 10.1002/2211-5463.12248. PubMed DOI PMC

Zhou S., et al. MicroRNA-199b-5p attenuates TGF-β1-induced epithelial–mesenchymal transition in hepatocellular carcinoma. Br. J. Cancer. Jul. 2017;117(2):233–244. doi: 10.1038/bjc.2017.164. PubMed DOI PMC

Eldosoky M.A., et al. Diagnostic significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p panel and ratios in hepatocellular carcinoma on top of liver cirrhosis in HCV-infected patients. Int. J. Mol. Sci. Feb. 2023;24(4):3157. doi: 10.3390/ijms24043157. PubMed DOI PMC

Atta S., et al. MicroRNA-199: a potential therapeutic tool for hepatocellular carcinoma in an experimental model. Asian Pac. J. Cancer Prev. APJCP. Sep. 2021;22(9):2771–2779. doi: 10.31557/APJCP.2021.22.9.2771. PubMed DOI PMC

Komoll R.M., et al. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J. Hepatol. Jan. 2021;74(1):122–134. doi: 10.1016/J.JHEP.2020.07.039. PubMed DOI

Wang G., et al. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma. BMC Cancer. Dec. 2017;17(1):805. doi: 10.1186/s12885-017-3816-1. PubMed DOI PMC

Sun Z., et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. Dec. 2014;14(1):616. doi: 10.1186/1471-2407-14-616. PubMed DOI PMC

Chen Q., et al. miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma via a positive feedback loop involving FOXO3/PI3K/AKT/c-Myc. World J. Stem Cell. 2022;14(7):539–555. doi: 10.4252/WJSC.V14.I7.539. PubMed DOI PMC

Debes J., Romagnoli P., Prieto J., Arrese M., Mattos A., Boonstra A. Serum biomarkers for the prediction of hepatocellular carcinoma. Cancers. Apr. 2021;13(7):1681. doi: 10.3390/cancers13071681. PubMed DOI PMC

Long X.-R., Zhang Y.-J., Zhang M.-Y., Chen K., Zheng X.F.S., Wang H.-Y. Identification of an 88-microRNA signature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases. Aging. Jun. 2017;9(6):1565–1584. doi: 10.18632/aging.101253. PubMed DOI PMC

Moshiri F., et al. Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget. Mar. 2018;9(20):15350–15364. doi: 10.18632/oncotarget.24601. PubMed DOI PMC

Shaheen N.M.H., et al. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. Virus Res. Aug. 2018;255:77–84. doi: 10.1016/j.virusres.2018.07.004. PubMed DOI

Amr K.S., Elmawgoud Atia H.A., Elazeem Elbnhawy R.A., Ezzat W.M. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis. Dec. 2017;4(4):215–221. doi: 10.1016/j.gendis.2017.10.003. PubMed DOI PMC

Chen T. Circulating non-coding RNAs as potential diagnostic biomarkers in hepatocellular carcinoma. J. Hepatocell. Carcinoma. Sep. 2022;9:1029–1040. doi: 10.2147/JHC.S380237. PubMed DOI PMC

Zhao H., Liu C., Zhao C., Che C., Liu W., Mei Y. Alternatively-spliced lncRNA-PNUTS promotes HCC cell EMT via regulating ZEB1 expression. Tumori J. Feb. 2023;109(1):28–37. doi: 10.1177/03008916211072585. PubMed DOI

Peng L., et al. LINC02273 promotes hepatocellular carcinoma progression via retaining β-catenin in the nucleus to augment Wnt signaling. BioMed Res. Int. Jan. 2022;2022:1–9. doi: 10.1155/2022/9631036. PubMed DOI PMC

Sun J., et al. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells. Acta Biochim. Biophys. Sin. Feb. 2022;54(2):261–270. doi: 10.3724/abbs.2021019. PubMed DOI PMC

Li D., et al. LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/SOSC2 axis. Aging. Jan. 2022;14(1):368–388. doi: 10.18632/aging.203813. PubMed DOI PMC

Qiu L., Wang T., Xu X., Wu Y., Tang Q., Chen K. Long non-coding rnas in hepatitis b virus-related hepatocellular carcinoma: regulation, functions, and underlying mechanisms. Int. J. Mol. Sci. Dec. 01, 2017;18(12) doi: 10.3390/ijms18122505. MDPI AG. PubMed DOI PMC

Zhang X., Zhou Y., Chen S., Li W., Chen W., Gu W. LncRNA MACC1-AS1 sponges multiple miRNAs and RNA-binding protein PTBP1. Oncogenesis. Dec. 2019;8(12):73. doi: 10.1038/s41389-019-0182-7. PubMed DOI PMC

Xiong H., et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. Jun. 2017;36(25):3528–3540. doi: 10.1038/onc.2016.521. PubMed DOI

Li X., et al. LncRNA NEAT1 promotes autophagy via regulating miR‐204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. J. Cell. Physiol. Apr. 2020;235(4):3402–3413. doi: 10.1002/jcp.29230. PubMed DOI

Zhou M., et al. Rutin attenuates sorafenib-induced chemoresistance and autophagy in hepatocellular carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis. Int. J. Biol. Sci. 2021;17(13):3595–3607. doi: 10.7150/ijbs.62471. PubMed DOI PMC

Zhao L., et al. lncRNA miat functions as a ceRNA to upregulate sirt1 by sponging miR-22-3p in HCC cellular senescence. Aging. Sep. 2019;11(17):7098–7122. doi: 10.18632/AGING.102240. PubMed DOI PMC

Huang X., Gao Y., Qin J., Lu S. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. Am. J. Physiol. Gastrointest. Liver Physiol. May 2018;314(5):G559–G565. doi: 10.1152/AJPGI.00242.2017. PubMed DOI

Wang Y., et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol. Cancer. Feb. 2019;18(1) doi: 10.1186/S12943-019-0957-7. PubMed DOI PMC

Xiao Z., Shen J., Zhang L., Li M., Hu W., Cho C. “Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: recent progress and future prospects. Oncol. Lett. Mar. 01, 2018;15(3):3395–3402. doi: 10.3892/ol.2018.7758. (review) Spandidos Publications. PubMed DOI PMC

Wang H., et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol. Cancer. Aug. 2017;16(1) doi: 10.1186/S12943-017-0680-1. PubMed DOI PMC

Chen J., et al. LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis. Aging. Nov. 2018;10(11):3371–3381. doi: 10.18632/AGING.101645. PubMed DOI PMC

Li Z., Wu G., Li J., Wang Y., Ju X., Jiang W. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC. BMC Cancer. Apr. 2020;20(1) doi: 10.1186/S12885-020-06771-Y. PubMed DOI PMC

Liu Z., et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. May 2019;38(1) doi: 10.1186/S13046-019-1188-X. PubMed DOI PMC

Huang Y., Xiang B., Liu Y., Wang Y., Kan H. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. Nov. 2018;437:56–66. doi: 10.1016/J.CANLET.2018.08.024. PubMed DOI

Kim S.S., et al. Serum small extracellular vesicle‐derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol. Oncol. Oct. 2020;14(10):2646–2659. doi: 10.1002/1878-0261.12745. PubMed DOI PMC

Wu Y., et al. RNA sequencing analysis reveals the competing endogenous RNAs interplay in resected hepatocellular carcinoma patients who received interferon-alpha therapy. Cancer Cell Int. Dec. 2021;21(1) doi: 10.1186/s12935-021-02170-w. PubMed DOI PMC

Sun L., et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J. Cancer. 2018;9(15):2631–2639. doi: 10.7150/jca.24978. PubMed DOI PMC

Lim L.J., et al. Highly deregulated lncRNA LOC is associated with overall worse prognosis in Hepatocellular Carcinoma patients. J. Cancer. 2021;12(11):3098–3113. doi: 10.7150/jca.56340. PubMed DOI PMC

Xu Z., et al. Construction of a ferroptosis-related nine-lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma. Front. Immunol. Sep. 2021;12 doi: 10.3389/fimmu.2021.719175. PubMed DOI PMC

Li Y., et al. <p>A novel lncRNA NONHSAT053785 acts as an independent risk factor for intrahepatic metastasis of hepatocellular carcinoma</p>. OncoTargets Ther. Jun. 2020;13:5455–5466. doi: 10.2147/OTT.S254455. PubMed DOI PMC

Xu X., et al. LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression. Cell Death Dis. Oct. 2019;10(10):752. doi: 10.1038/s41419-019-1990-6. PubMed DOI PMC

Yao Z., et al. Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma. Aging. Jun. 2020;12(12):11843–11863. doi: 10.18632/aging.103355. PubMed DOI PMC

Yang J., Liu F., Wang Y., Qu L., Lin A. LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling. Cancer Lett. Sep. 2022;543 doi: 10.1016/j.canlet.2022.215798. PubMed DOI

Lin Y., et al. Taurine up‐regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology. Jan. 2018;67(1):188–203. doi: 10.1002/hep.29462. PubMed DOI

Cao S.-Q., et al. Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion. World J. Gastroenterol. Sep. 2019;25(35):5283–5299. doi: 10.3748/wjg.v25.i35.5283. PubMed DOI PMC

Gao J., Yin X., Yu X., Dai C., Zhou F. Long noncoding RNA LINC00488 functions as a ceRNA to regulate hepatocellular carcinoma cell growth and angiogenesis through miR-330-5. Dig. Liver Dis. Jul. 2019;51(7):1050–1059. doi: 10.1016/j.dld.2019.03.012. PubMed DOI

Tian X., et al. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β‐catenin signaling. Mol. Oncol. Feb. 2020;14(2):462–483. doi: 10.1002/1878-0261.12606. PubMed DOI PMC

Zhang Y., Huang B., Chen Z., Yang S. <p>Knockdown of LINC00473 enhances radiosensitivity in hepatocellular carcinoma via regulating the miR-345-5p/FOXP1 Axis</p>. OncoTargets Ther. Jan. 2020;13:173–183. doi: 10.2147/OTT.S240113. PubMed DOI PMC

Sui C., et al. LncRNA FOXD2‐AS1 as a competitive endogenous RNA against miR‐150‐5p reverses resistance to sorafenib in hepatocellular carcinoma. J. Cell Mol. Med. Sep. 2019;23(9):6024–6033. doi: 10.1111/jcmm.14465. PubMed DOI PMC

Ye J., Zhang R., Du X., Chai W., Zhou Q. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p. OncoTargets Ther. Jan. 2019;ume 12:415–422. doi: 10.2147/OTT.S175176. PubMed DOI PMC

Li S., et al. SNHG16 as the miRNA let‐7b‐5p sponge facilitates the G2/M and epithelial‐mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma. J. Cell. Biochem. Mar. 2020;121(3):2543–2558. doi: 10.1002/jcb.29477. PubMed DOI

Liang C., et al. LncRNA GAS6-AS2 facilitates tumor growth and metastasis of hepatocellular carcinoma by activating the PI3K/AKT/FoxO3a signaling pathway. Int. J. Clin. Exp. Pathol. 2019;12(11):4011–4023. PubMed PMC

Jin Y., et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci. Rep. Jul. 2019;9(1) doi: 10.1038/s41598-019-46872-8. PubMed DOI PMC

Shi W., et al. Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma. Medicine. Aug. 2017;96(32):e7764. doi: 10.1097/MD.0000000000007764. PubMed DOI PMC

Verma S., Sahu B.D., Mugale M.N. Role of lncRNAs in hepatocellular carcinoma. Life Sci. Jul. 2023;325 doi: 10.1016/j.lfs.2023.121751. PubMed DOI

Kabir T.D., et al. A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma. Hepatology. Jan. 2018;67(1):216–231. doi: 10.1002/hep.29478. PubMed DOI

Zhang K., et al. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis. Feb. 2018;9(3):312. doi: 10.1038/s41419-018-0344-0. PubMed DOI PMC

Hassan M., Elzallat M., Aboushousha T., Elhusseny Y., El-Ahwany E. MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma. Noncoding RNA Res. Mar. 2023;8(1):126–134. doi: 10.1016/j.ncrna.2022.11.005. PubMed DOI PMC

Yuan D., et al. Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis. Int. J. Biol. Sci. 2021;17(1):220–235. doi: 10.7150/ijbs.50730. PubMed DOI PMC

Sanoff H.K., Chang Y., Lund J.L., O'Neil B.H., Dusetzina S.B. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncol. Sep. 2016;21(9):1113–1120. doi: 10.1634/theoncologist.2015-0478. PubMed DOI PMC

Zhu Y., Zheng B., Wang H., Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol. Sin. May 2017;38(5):614–622. doi: 10.1038/aps.2017.5. PubMed DOI PMC